Find an Article

Filter articles

Applied Filters

Showing 111 to 120 of 312 results

Pharma collaboration in Russia: the dos and don’ts

Russia15-12-2016Natalia Gulyaeva and Maria Sedykh

Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.

Life sciences transactions: look before you leap

US06-12-2016Karen Mangasarian and Ryan Murphey

Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.

Patenting genes: how do India and the US compare?

India, US17-11-2016Swarup Kumar

India’s position on patenting genes borrows heavily from that of the US, but will the status quo change? Swarup Kumar of Remfry & Sagar reports.

Arrow declarations: striking at the heart of commercial uncertainty

EU, UK08-11-2016Richard Roberts

To overcome a crowded patent market, a potential solution is to seek a declaration of obviousness, which has a basis in UK law stemming from Arrow Generics v Merck. Richard Roberts of Potter Clarkson reports.

IP Life Sciences Exchange: a preview


The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

IP service providers: a more cost-effective solution post M&A?

International18-10-2016Melissa Pillote

With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.

Pay-for-delay: Play by the rules

EU14-10-2016Bernd Allekotte and Franz Zimmer

The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.

The post-Brexit picture for orphan drugs

EU, UK13-10-2016Kei Enomoto

The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.

Life Technologies v Promega: the long tentacles of infringement

US12-10-2016Sandra Kuzmich and Russell Garman

Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain.

Working together wisely

International12-10-2016Oliver Laing and Tony Proctor

In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.

Showing 111 to 120 of 312 results